Using MRI and computer analysis to assess prostate cancer aggressiveness
Can Magnetic Resonance Imaging of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour (Can MRI-PREDICT)
This study is testing if using MRI and computer analysis can help doctors better understand how aggressive prostate cancer is, which could lead to more effective treatment choices for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Sex | Male |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT05024162 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the accuracy of prostate cancer diagnosis by utilizing magnetic resonance imaging (MRI) combined with a radiomics evaluation. The researchers have developed a machine-learning algorithm that analyzes MRI characteristics to predict the aggressiveness of prostate tumors, which could lead to better treatment decisions. Participants will undergo two MRI scans within a short timeframe to validate the predictive model against traditional biopsy results. The goal is to improve the reproducibility and reliability of MRI assessments in prostate cancer.
Who should consider this trial
Good fit: Ideal candidates are men with a detectable prostate nodule on MRI that has been confirmed by biopsy as prostate cancer.
Not a fit: Patients who have undergone prior prostatic interventions or have altered testosterone levels may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and personalized treatment plans for prostate cancer patients.
How similar studies have performed: Other studies have shown promise in using MRI and radiomics for cancer diagnosis, but this specific approach is novel and aims to address existing limitations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: An appropriate diagnostic MRI-P, defined as: * Being performed on 3T MRI at the Halifax Infirmary Building * Taken place within 5 weeks of study enrolment * Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen * Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate An appropriate diagnostic biopsy, defined as: * Taken place within 2 months of the participant's MRI-P 1 * Taken place within 3 months of participant's study enrolment * Reports diagnosis of PCa * Reports a systematic assessment of the biopsy, assessing at least 12 cores * Reports at least on core involved with PCa and this core must anatomically localise to a nodule seen on MRI-P 1 Exclusion Criteria: * Past prostatic interventions which would influence the prostate's structure * Alterations to physiological testosterone levels * Inability to position one's self in a reproducible fashion for an MRI-P * Patient factors reported to produce significant artifact on MRI-P 1
Where this trial is running
Halifax, Nova Scotia
- Victoria General Hospital — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Principal investigator: Dr. Michael Kucharczyk — Nova Scotia Health Authority
- Study coordinator: Beverly A Lieuwen, BSc
- Email: beverly.lieuwen@iwk.nshealth.ca
- Phone: 9024735315
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.